Prediction of aryl hydrocarbon receptor-mediated enzyme induction of drugs and chemicals by mRNA quantification

被引:17
作者
Frötschl, R
Chichmanov, L
Kleeberg, U
Hildebrandt, AG
Roots, I
Brockmöller, J
机构
[1] Humboldt Univ, Univ Klinikum Charite, Inst Klin Pharmakol, D-10098 Berlin, Germany
[2] Fed Inst Drugs & Med Devices, D-13353 Berlin, Germany
关键词
D O I
10.1021/tx980164h
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Enzyme-specific testing for drug interactions by in vitro techniques has become a routine practice in drug development. With many drugs, enzyme induction has similar importance for the prediction of drug-drug interactions. We developed a method for recognizing enzyme induction mediated via the aryl hydrocarbon receptor. This type of induction may be clinically important since experimental data suggest a higher rate of toxification in induced subjects, Twenty-four drugs and environmental chemicals, selected as prototype inducers or being chemically related to known inducers, including HIV protease inhibitors nelfinavir, saquinavir, ritonavir, and indinavir, were tested for their potency to induce cytochrome P450 1A1 mRNA in human Hela cell cultures by a quantitative reverse transcriptase polymerase chain reaction. Known prototype inducers such as beta-naphthoflavone and 3-methylcholanthrene exhibited the highest inducing potency quantified with an I-max value (maximal induction of cytochrome P450 1A1 mRNA synthesis) of 5.48 and 10.7 x 10(6) mRNA molecules per 150 ng of total RNA, respectively. The enzyme-inducing efficacy of some compounds such as resveratrol (2.92 x 106) and the protease inhibitors was not much lower (2.23-3.08 x 10(6)). All compounds that were structurally similar to benzimidazoles exhibited some extent of enzyme induction; e.g I-max values were 0.86 x 10(6), 0.20 x 10(6), and 0.14, x 10(6) for omeprazole, lansoprazole, and losartan, respectively. To predict the clinical relevance of these inducing effects, the concentration at half-maximal induction I-M was estimated the plasma concentrations of these drug substances were within 1 order of magnitude of the I-M values, upon usual dosage. In conclusion, cytochrome P450 1A1 enzyme induction by drugs is a common phenomenon, though there is a great range in the inducing efficacy. In vitro prediction of enzyme induction may be useful for explaining or foreseeing drug inter actions, drug side effects, or toxicity by xenobiotics.
引用
收藏
页码:1447 / 1452
页数:6
相关论文
共 47 条
  • [1] Alexander DL, 1997, CANCER RES, V57, P4498
  • [2] Brockmoeller J., 1997, European Journal of Clinical Pharmacology, V52, pA186
  • [3] HUMAN CYTOCHROME P-450PA (P-450IA2), THE PHENACETIN O-DEETHYLASE, IS PRIMARILY RESPONSIBLE FOR THE HEPATIC 3-DEMETHYLATION OF CAFFEINE AND N-OXIDATION OF CARCINOGENIC ARYLAMINES - (AROMATIC-AMINES HETEROCYCLIC AMINES CARCINOGEN METABOLISM)
    BUTLER, MA
    IWASAKI, M
    GUENGERICH, FP
    KADLUBAR, FF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) : 7696 - 7700
  • [4] GENETIC-POLYMORPHISM OF INDUCTION OF CYP1A1 (EROD) ACTIVITY
    CATTEAU, A
    DOURIEZ, E
    BEAUNE, P
    POISSON, N
    BONAITIPELLIE, C
    LAURENT, P
    [J]. PHARMACOGENETICS, 1995, 5 (02): : 110 - 119
  • [5] SYNERGISTIC ACTIVITY OF POLYNUCLEAR AROMATIC HYDROCARBON MIXTURES AS ARYL-HYDROCARBON (AH) RECEPTOR AGONISTS
    CHALOUPKA, K
    HARPER, N
    KRISHNAN, V
    SANTOSTEFANO, M
    RODRIGUEZ, LV
    SAFE, S
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 1993, 89 (2-3) : 141 - 158
  • [6] CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
  • [7] CONNEY AH, 1982, CANCER RES, V42, P4875
  • [8] Induction of CYP1A1 gene by benzimidazole derivatives during Caco-2 cell differentiation - Evidence for an aryl-hydrocarbon receptor-mediated mechanism
    Daujat, M
    Charrasse, S
    Fabre, I
    Lesca, P
    Jounaidi, Y
    Larroque, C
    Poellinger, L
    Maurel, P
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 237 (03): : 642 - 652
  • [9] OMEPRAZOLE, AN INDUCER OF HUMAN CYP1A1 AND 1A2, IS NOT A LIGAND FOR THE AH RECEPTOR
    DAUJAT, M
    PERYT, B
    LESCA, P
    FOURTANIER, G
    DOMERGUE, J
    MAUREL, P
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 188 (02) : 820 - 825
  • [10] Delaporte E, 1998, CLIN PHARMACOL THER, V63, P149